Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-19T10:32:47.708Z Has data issue: false hasContentIssue false

A comparison of plague vaccines by the mouse protection test

Published online by Cambridge University Press:  15 May 2009

F. E. Bucklakd
Affiliation:
Microbiological Research Establishment, Porton, nr Salisbury, Wilts
R. H. Treadwell
Affiliation:
Microbiological Research Establishment, Porton, nr Salisbury, Wilts
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

1. In our hands the assay of a plague vaccine, in terms of its power to protect mice against what was hoped to be a standard challenge, was found to be impracticable.

2. Assay by mouse protection tests in terms of a Standard vaccine was found to be possible, but it proved to be a very time-consuming procedure and demanded the use of an almost prohibitively large number of mice for a sufficient number of replicate tests which are required to offset the variability in the method. Theoretically a single test might be adequate if the numbers of immunized mice were very large, but there are obvious limitations to the numbers of mice that can be included in a single test of this nature.

3. The Ouchterlony plate technique proved to be useful in indicating the antigens present in a particular vaccine, but not on a strictly quantitative basis.

4. The vaccine prepared from the virulent human strain of P. pestis was found to protect mice more efficiently than those prepared from avirulent strains and when the protective potency was expressed in terms of content of antigen and high molecular weight substances the vaccine prepared from the virulent culture was found to be even more potent than the Standard acetone-dried vaccine.

5. The use of formalin as a preservative results in some loss of potency of a vaccine but, provided the strain of P. pestis used for the preparation of the vaccine is highly virulent, this need not be serious and is offset by a number of advantages.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1961

References

REFERENCES

Baker, E. E., Sommer, H., Foster, L. E., Meyer, E. & Meyer, F. K. (1952). J. Immunol. 68, 131.CrossRefGoogle Scholar
Burrows, T. W. & Bacon, G. A. (1954). Brit. J. exp. Path. 35, 129.Google Scholar
Crumpton, M. J. & Davies, D. A. L. (1956). Proc. Roy. Soc. B, 145, 109.Google Scholar
Finney, D. J. (1947). Probit Analysis. Cambridge University Press.Google Scholar
Miles, A. A. & Misra, S. S. (1938). J. Hyg., Camb., 38, 732.Google Scholar
Reed, L. J. & Muench, H. (1938). Amer. J. Hyg. 27, 493.Google Scholar